The Global Innovation Model for Antibiotics Needs Reinvention

Butler M. S. Blaskovich M. A. Cooper M. A. , “Antibiotics in the Clinical Pipeline in 2013,” Journal of Antibiotics 66 (2013): 571–599.

Outterson K. , New Business Models for Sustainable Antibiotics (Chatham House, London: Royal Institute of International Affairs, 2014).

Outterson K. Powers J. H. Daniel G. W. McClellan M. B. , “Repairing the Broken Market for Antibiotic Innovation,” Health Affairs 34, no. 2 (2015): 277–285.

Report on the event, “Best Use of Medicines Legislation to Bring New Antibiotics to Patients and Combat the Resistance Problem,” European Medicines Agency, London, November 2013, available at <http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/12/WC500158230.pdf> (last visited May 14, 2015).

World Health Organization, Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination , Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (2012), available at <http://www.who.int/phi/CEWG_Report_5_April_2012.pdf?ua=1> (last visited May 14, 2015).

Hollis A. Maybarduk P. , “Antibiotic Resistance Is a Tragedy of the Commons That Necessitates Global Cooperation,” Journal of Law, Medicine & Ethics 43, no. 2 (2015): Available via aslme.org.

Jaczynska E. Outterson K. Mestre-Farrandiz J. , Business Model Options for Antibiotics: Learning from Other Industries (Big Innovation Centre/Chatham House, London: Royal Institute of International Affairs, 2015); Chatham House Working Group, New Antibiotic Business Model (Chatham House, London: Royal Institute of International Affairs, 2015).

See Hollis , supra note 6.

Longitude Prize, available at <https://longitudeprize.org/> (last visited May 14, 2015); Gavi , “Pneumococcal AMC,” available at <http://www.gavi.org/funding/pneumococcal-amc/> (last visited May 14, 2015).

Follow-up of the report on the Consultative Expert Working Group on Research and Development: Financing and Coordination, available at <http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_28Add1-en.pdf> (last visited May 14, 2015).

Hoffmann S. J. Outterson K. Røttingen J. A. Cars O. Clift C. Rizvi Z. Rotberg F. Tomson G. Zorset A. , “An International Legal Framework to Address Antimicrobial Resistance,” Bulletin of the World Health Organization (2015): 93/2/15–152710.

Røttingen J. A. Regmi S. Eide M. Young A. J. Viergever R. F. Årdal C. Guzman J. Edwards D. Matlin S. A. Terry R. F. , “Mapping Available Health R&D Data: What's There, What's Missing and What Role for a Global Observatory,” The Lancet 382, no. 9900 (2013): 1286–1307.

Grogan K. , “AMR Review Head O'Neill Calls for $2 Billion Innovation Fund,” Pharma Times, available at <http://www.pharmatimes.com/Article/15-02-27/AMR_review_head_O_Neill_calls_for_2_billion_innovation_fund.aspx> (last visited May 14, 2015).

Jamison D. T. Summers L. H. Alleyne G. , “Global Health 2035: A World Converging within a Generation,” The Lancet 382, no. 9908 (2013): 1898–1955.

President's Council of Advisors on Science & Technology, Report to the President on Combating Antibiotic-Resistant Bacteria (September 2014) at 3, available at <https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf> (last visited May 14, 2015).

See WHO, supra note 5; Holli , supra note 6; Jaczynska , supra note 7.

World Health Organization, “Innovation for Antibiotics Development and Preservation,” available at <http://www.who.int/phi/implementation/consultation_imnadp/en/> (last visited May 14, 2015).